142217-79-6

Basic information

• Product Name: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone
• Synonyms: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone;Entecavir interMediate 6;(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-Methoxyphenyl)diphenylMethyl]aMino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxyMethyl)cyclopentanone (interMediate step 5);(2R,3S,5S)-3-(Benzyloxy)-5-(6-(benzyloxy)-2-(((4-methoxyphenyl)diphenylmethyl)-amino)-9H-purin-9-;EntecavirinterMediate;(2R,3S,5S)-3-(Benzyloxy)-5-(6-(benzyloxy)-2-(((4-Methoxyphenyl)diphenylMethyl)aMino)-9H-purin-9-yl)-2-((benzyloxy)Methyl)cyclopentanone;(2R,3S,5S)-3-(Benzyloxy)-5-(6-(benzyloxy)-2-(((4-methoxyphenyl)diphenylmethyl)-amino)-9H-purin;Entecavir Impurity 2
• CAS NO: 142217-79-6
• Molecular Formula: C₅₂H₄₇N₅O₅
• Molecular Weight: 821.96
• Mol File: 142217-79-6.mol

Chemical Properties

• Appearance: /
• Density: 1.23
• Refractive Index: 1.645
• Storage Temp.: 2-8°C
• PKA: 2.75±0.30(Predicted)
• CAS DataBase Reference: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone(CAS DataBase Reference)
• NIST Chemistry Reference: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone(142217-79-6)
• EPA Substance Registry System: (2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone(142217-79-6)

Safety Data

• Hazardous Substances Data: 142217-79-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone is used as a potential drug candidate for its potential central nervous system activity. The presence of the purine group indicates that it may interact with various biological targets, making it a promising candidate for further research and development in the pharmaceutical field.
Used in Drug Development Research:
This complex compound is used as a subject of study in drug development research to explore its potential interactions with biological targets and its efficacy in treating central nervous system disorders. Its unique structure and multiple functional groups provide opportunities for understanding its mechanism of action and optimizing its therapeutic potential.
Used in Medicinal Chemistry:
(2R,3S,5S)-3-(Benzyloxy)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-(benzyloxy)-9H-purin-9-yl]-2-(benzyloxymethyl)cyclopentanone is utilized in medicinal chemistry for the synthesis of novel compounds with potential therapeutic applications. Its complex structure allows for the exploration of various chemical modifications to enhance its pharmacological properties and improve its drug-like characteristics.

InChI:InChI=1/C52H47N5O5/c1-59-43-29-27-42(28-30-43)52(40-23-13-5-14-24-40,41-25-15-6-16-26-41)56-51-54-49-47(50(55-51)62-34-39-21-11-4-12-22-39)53-36-57(49)45-31-46(61-33-38-19-9-3-10-20-38)44(48(45)58)35-60-32-37-17-7-2-8-18-37/h2-30,36,44-46H,31-35H2,1H3,(H,54,55,56)/t44-,45+,46+/m1/s1

Upstream product

• 3587-60-8 Benzyloxymethyl chloride 
• 110567-22-1 (2R,3S)-benzyloxy-2-benzyloxymethyl-6-oxabicyclo<3.1.0>hexane 
• 142217-77-4 [1S-(1α,2β,3α,5β)]-5-(2-amino-6-benzyloxy-9H-purin-9-yl)-3-benzyloxy-2-(benzyloxy)methyl-cyclopentanol 
• 4984-82-1 sodium cyclopentadienylide 
• 14470-28-1 mono-4-methoxytrityl chloride 
• 110567-21-0 (1S,2R)-2-(benzyloxymethyl)-1-hydroxy-3-cyclopentene 
• 117641-39-1 (2R,3S)-2-benzyloxymethyl-6-oxabicyclo<3.1.0>hexan-3-ol 
• 39939-07-6 5-(benzyloxymethyl)cyclopentadiene 
• 142217-78-5 (1S,2S,3S,5S)-5-[2-[[(4-methoxyphenyl)diphenylmethyl]amino]-6-benzyloxy-9H-purin-9-yl]-3-benzyloxy-2-[(benzyloxy)methyl]cyclopentanol 

Downstream Products

• 142217-80-9 6-(benzyloxy)-9-((1S,3R,4S)-4-(benzyloxy)-3-((benzyloxy)methyl)-2-methylidenecyclopentyl)-N-((4-methoxyphenyl)diphenylmethyl)-9H-purin-2-amine 
• 142217-69-4 entecavir 
• 142217-81-0 2-amino-1,9-dihydro-9-[(1S,3R,4S)-2-methylene-4-(phenylmethoxy)-3-[(phenylmethoxy)methyl]cyclopentyl]-6H-purin-6-one 

Relevant articles and documents

Improved entecavir intermediate synthesis process and improved entecavir synthesis process

The invention discloses an improved entecavir intermediate synthesis process and an improved entecavir synthesis process, and relates to the technical field of drug synthesis. The invention disclosesan improved entecavir intermediate synthesis process. In the synthesis process of an amino protection reaction product, amino protecting groups are added in batches; and the ratio of the reaction rawmaterials is optimized, so that the problems of long reaction time and relatively low amino protection reaction yield due to adoption of a one-time complete feeding mode in an existing synthesis modeare solved, the synthesis time of an amino protection reaction product is shortened to 50-70 minutes, and the obtained product is high in yield and purity. According to the improved entecavir synthesis process, in the amino protection reaction product synthesis process, reaction conditions are effectively optimized, and the purity of obtained entecavir reaches 99% or above.

A method for the preparation of entecavir (by machine translation)

The invention discloses a compound of formula (I) shown in the method for the preparation of entecavir, the method according to the following steps: shown in formula (II) intermediate of the raw materials, as shown in formula (III) of the polystyrene load the high price of iodine is the oxidizing agent, in order to of a catalytic amount of N - hydroxy imide compound as co-oxidizing agent, under the action of the additive, in formula (I). The beneficial effect of the present invention is of relatively expensive the iodine passes through polystyrene after load, can be a simple filtration recovery, recycling, the production cost is low, the preparation method is suitable for industrial production. (by machine translation)

BMS-200475, a novel carbocyclic 2'-deoxyguanosine analog with potent and selective anti-hepatitis B virus activity in vitro

BMS-200475, a never carbocyclic analog of 2'-deoxyguanosine, is a potent inhibitor of hepatitis B virus in vitro (ED50 = 3 nM) with relatively low cytotoxicity (CC50 = 21-120 μM). A practical 10-step asymmetric synthesis was developed affording BMS-200475 in 18% overall chemical yield and > 99% optical purity. The enantiomer of BMS-200475 as well as the adenine, thymine, and iodouracil analogs are much less active.